Navamepent

DB21096InvestigationalSmall molecule

Navamepent is a small molecule drug. Navamepent is under investigation in clinical trial NCT02329743 (Efficacy and Safety of RX-10045 Ophthalmic Solution for Ocular Inflammation and Pain in Cataract Surgery). Navamepent... Navamepent has a monoisotopic molecular weight of 304.17 Da.

Formula / weight: C₁₈H₂₄O₄ · 304.386 g/mol (avg)
Code names: RX-10045

Resolves to

Compound

UNIIQ7789B8MWMCAS1251537-11-7ChEMBLCHEMBL5314965ChEBI759656PubChem46926878

Structure

InChIKeyZVOCIIHCJJEFRQ-BHXBHYJPSA-NSMILESCC(C)OC(=O)CCC[C@H](O)C#C\C=C\C=C\[C@H](O)CC#C

Transporters

P08183ABCB1Q9UNQ0ABCG2Q92887ABCC2O15245SLC22A1

What you can answer from here — as of September 23, 2026

4TransportersSubstrate / inhibitor direction, not just membership

Listed above

3Clinical trialsPhase, status and sponsor resolved per trial

4+ReferencesStructured and connected to the statements they support

Which companies are running trials of Navamepent, in which indications and phases, and which of those programs are still active?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account